Michael Serzan: About the hottest new ICI BOTENSILIMAB in Kidney Cancer?
Michael Serzan, Genitourinary Medical Oncologist from Dana-Farber Cancer Institute, shared on X:
” Interested in learning about the hottest new ICI BOTENSILIMAB in Kidney Cancer?
Follow the thread below and check out TIP Poster at ASCO GU24, Saturday 01/27/24 7-8am, 1130-1pm
ARCITECT
RP2 @ 13 sites
ALL Risk ccRCC, no prior Tx
ArmA: BOT/BAL (80)
ArmB: NIVO/IPI (40)
BACKGROUND
NIVO/IPI has robust landmark PFS, OS, and TFS – CM214 (CheckMate 214)
What mediates resistance to anti-PD1 in RCC?
Data from Signoretti Lab shows that Treg in the tumor microenvironment are critical to PD1 resistance.
Can we target Treg in the TME?
BOTENSILIMAB is a novel Fc-enhanced CLTA inhibitor that has shown efficacy in cold tumors due to novel features:
1️⃣ Treg depletion
2️⃣ Enhance T cell priming and antigenicity
3️⃣ Decrease complement-mediated toxicity
Recent Data across multiple tumors
📍MSS colon cancer – NEST1 at ASCO GI24 by Pashtoon Kasi
📍Refractory Sarcoma – ESMO23 by Breelyn Wilky and Liz Connolly
📍Ongoing trial in Lung Cancer – by Mark Awad
Come check out TIP poster at ASCO GU24 Saturday 01/27/24 7-8am, 1130-1pm to learn more about:
💉novel dosing strategy
⚠️ICI tox mgmt
✍️ IIT development/ mentorship
BONUS we can exchange favorite Peleton rides and coffee recs.
Grateful for the greatest mentors on the planet Toni Choueiri, Bradley McGregor, Dr. Atkins & ARCITECT investigators for their continual support developing this INVESTIGATOR INITIATED TRIAL opening at 13 HCRN sites
Science is HARD WORK but teamwork makes the dream work!
FIN”
Source: Michael Serzan /X